YouTube Facebook LinkedIn Google+ Twitter Xingrss  

Big Claims, Big Promise?


December 11, 2012 | Moderna Therapeutics has billed itself the next Genentech. It's raised more than $40 milion and has attracted some big names for its Scientific Advisory Board. But questions remain about the company's RNA technology. How will the technology achieve the right therapeutic dose level? And is the mRNA approach really better than some of the long-acting proteins now on the market? Technology Review
View Next Related Story
Click here to login and leave a comment.  

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1


For reprints and/or copyright permission, please contact  Terry Manning, 781.972.1349 , tmanning@healthtech.com.